赛托生物(300583) - 2024 Q1 - 季度财报

Revenue and Profit - The company's revenue for Q1 2024 was ¥244,395,524.04, a decrease of 27.00% compared to ¥334,785,915.82 in the same period last year[4] - Net profit attributable to shareholders was ¥3,070,728.65, down 80.00% from ¥15,355,110.28 year-on-year[4] - The company reported a basic earnings per share of ¥0.02, down 77.78% from ¥0.09 in the same quarter last year[4] - Net profit for Q1 2024 was ¥3,711,472.71, a decline of 79% from ¥17,525,308.93 in Q1 2023[20] Cash Flow - The net cash flow from operating activities increased by 98.51% to ¥21,248,864.71, compared to ¥10,704,060.35 in Q1 2023[11] - The net cash flow from financing activities surged by 1,424.34% to ¥101,263,266.17, compared to ¥6,643,103.13 in Q1 2023[11] - The company received cash related to operating activities totaling ¥202,674,544.42, a decrease from ¥248,042,987.04 in the previous year[22] - In Q1 2024, the net cash flow from investing activities was -12,909,484.64, compared to -27,232,006.03 in Q1 2023, indicating an improvement[23] - The total cash inflow from financing activities was 536,827,460.79, up from 381,974,721.80 in the same quarter last year, reflecting a 40.6% increase[23] - The company experienced a net increase in cash and cash equivalents of 109,895,640.36 in Q1 2024, contrasting with a decrease of -11,191,652.48 in Q1 2023[23] Assets and Liabilities - Total assets at the end of Q1 2024 were ¥3,370,087,418.79, reflecting a 4.01% increase from ¥3,240,242,403.84 at the end of the previous year[4] - Total liabilities amounted to ¥1,299,942,942.85, compared to ¥1,174,795,832.63 previously[17] - The company reported cash and cash equivalents of ¥351,284,155.10 at the end of Q1 2024, an increase from ¥238,490,756.82 at the beginning of the period[16] - Accounts receivable stood at ¥271,654,095.00, slightly down from ¥272,117,151.74[16] - Inventory increased to ¥730,067,778.48 from ¥722,624,129.92, indicating a growth in stock levels[16] Shareholder Information - Total number of common shareholders at the end of the reporting period is 12,521[13] - The largest shareholder, Shandong Runxin Investment Co., Ltd., holds 22.82% of shares, totaling 43,297,382 shares, with 15,280,000 shares pledged[13] Operating Costs and Expenses - The company’s operating costs decreased by 28.88% to ¥174,821,291.66, down from ¥245,803,460.08 in the previous year[9] - Total operating costs for Q1 2024 were ¥238,473,780.69, down 24% from ¥313,685,870.45 year-over-year[19] - Research and development expenses for Q1 2024 were ¥14,321,901.84, slightly up from ¥13,999,442.81 in Q1 2023[19] Equity and Investments - The company reported a total equity attributable to shareholders of the parent company of ¥2,016,119,568.37, up from ¥2,012,156,809.24 year-over-year[20] - Long-term investments increased to ¥67,022,673.30 from ¥65,119,540.60[16] - The company's equity remains stable with a share capital of ¥189,702,126.00[17] Other Financial Metrics - The weighted average return on equity decreased to 0.15% from 0.89% year-on-year, a decline of 0.74%[4] - Other comprehensive income after tax for Q1 2024 was ¥986,432.02, compared to a loss of ¥1,525,944.83 in Q1 2023[20] - The company has not reported any changes in the status of preferred shareholders or significant changes in shareholding structure[15] Audit Status - The first quarter report for 2024 was not audited, which may affect the reliability of the financial data presented[24]